Pfizer Inc. today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The ...

Dell's AI transformation is fully underway. This is how the company has changed this year and embraced two of the biggest ...

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Home Depot, Inc. (HD) and Pfizer ... on expanding supply chain facilities ...

Now, Pfizer and the trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) rank among the organizations that have helped Trump raise a record-setting $150 million in pledges ...

Overhaul, a startup developing supply chain risk monitoring software, has raised $55 million in a venture round.

The IRA makes significant changes to the Medicare Part D benefit design, which will impact Pfizer revenue in 2025, including: an expected favorable impact from the $2,000 annual out-of-pocket cap ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

As one of the largest vaccine makers, Pfizer has a big part of its business hinging on potential immunization policy changes under the incoming Trump administration. So when vaccine skeptic Robert F.